UY33976A - Derivados de pirazolo-pirimidina. - Google Patents
Derivados de pirazolo-pirimidina.Info
- Publication number
- UY33976A UY33976A UY0001033976A UY33976A UY33976A UY 33976 A UY33976 A UY 33976A UY 0001033976 A UY0001033976 A UY 0001033976A UY 33976 A UY33976 A UY 33976A UY 33976 A UY33976 A UY 33976A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirazolo
- pyrimidine
- derivatives
- página
- sgdd
- Prior art date
Links
- 241000950314 Figura Species 0.000 abstract 1
- FWYUJENICVGSJH-UHFFFAOYSA-M sodium;2-[bis[2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]-2-oxoethyl]amino]acetate Chemical compound [Na+].CC1=NC=C([N+]([O-])=O)N1CCOC(=O)CN(CC([O-])=O)CC(=O)OCCN1C([N+]([O-])=O)=CN=C1C FWYUJENICVGSJH-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a derivados de pirazolopirimidina,a métodos para su preparación, a combinaciones y composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento de enfermedades y trastornos que, por ejemplo, pueden involucrar enfermedades autoinmunes, angiogénesis, dolor, y/o enfermedades inflamatorias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470630P | 2011-04-01 | 2011-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33976A true UY33976A (es) | 2012-10-31 |
Family
ID=45976462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033976A UY33976A (es) | 2011-04-01 | 2012-03-28 | Derivados de pirazolo-pirimidina. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8748435B2 (es) |
EP (1) | EP2694513B1 (es) |
JP (1) | JP5963843B2 (es) |
KR (1) | KR20140023331A (es) |
CN (1) | CN103502248B (es) |
AR (1) | AR085750A1 (es) |
AU (1) | AU2012235665A1 (es) |
BR (1) | BR112013025001A2 (es) |
CA (1) | CA2831929A1 (es) |
EA (1) | EA201391440A1 (es) |
ES (1) | ES2534444T3 (es) |
MX (1) | MX2013011421A (es) |
PL (1) | PL2694513T3 (es) |
PT (1) | PT2694513E (es) |
TW (1) | TW201245203A (es) |
UY (1) | UY33976A (es) |
WO (1) | WO2012131633A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150216867A1 (en) * | 2012-09-25 | 2015-08-06 | Novartis Ag | Compounds for use in gastric complication |
CN105037373B (zh) * | 2015-07-13 | 2018-07-31 | 北京理工大学 | 一种合成吡唑并[3,4-d]嘧啶类化合物的方法 |
MA42023B2 (fr) * | 2015-07-20 | 2022-01-31 | Genzyme Corp | Inhibiteurs du récepteur de facteur-1 de stimulation de colonies (csf-1r) |
CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
GB201700692D0 (en) * | 2017-01-16 | 2017-03-01 | Salvensis | Novel compounds and their use in the treatment of schistosomiasis |
CN110636846B (zh) * | 2017-05-17 | 2023-05-16 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的喹唑啉吡唑衍生物 |
EP3932912A4 (en) * | 2019-02-28 | 2022-09-07 | Osaka University | MOLECULE FOR MODIFICATION BY A PROTEIN AND/OR A PEPTIDE |
EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
CN115304607B (zh) * | 2022-07-06 | 2023-06-27 | 华南农业大学 | 吡唑并嘧啶衍生物的制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2057089A1 (en) | 1990-12-07 | 1992-06-08 | Eric E. Allen | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists |
FR2690442A1 (fr) | 1992-04-27 | 1993-10-29 | Union Pharma Scient Appl | Nouveaux dérivés de pyrazolopyrimidine antagonistes des récepteurs à l'Angiotensine II; leurs procédés de préparation, compositions pharmaceutiques les contenant . |
JPH069638A (ja) | 1992-06-19 | 1994-01-18 | Ube Ind Ltd | ピラゾロピリミジン誘導体 |
DE4333705C2 (de) | 1993-10-02 | 2003-10-30 | Guenter Ege | Arylmethylsubstituierte Pyrazolo-azine, insbesondere 3-Arylmethylpyrazolo[1,5-a]pyrimidine und Verfahren zur Herstellung von 8-Arylmethyl-pyrazolo[5,1-c][1,2,4]triazinen |
JP3163412B2 (ja) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | ピラゾロ〔1,5−a〕ピリミジン誘導体 |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
US20020041880A1 (en) | 2000-07-05 | 2002-04-11 | Defeo-Jones Deborah | Method of treating cancer |
GB0016787D0 (en) | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
AU2001292867A1 (en) | 2000-09-20 | 2002-04-02 | The Cleveland Clinic Foundation | Ligands for g protein coupled receptors and methods of using them |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
CN100343255C (zh) | 2002-04-23 | 2007-10-17 | 盐野义制药株式会社 | 吡唑并[1,5-a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂 |
AU2003240589A1 (en) | 2002-05-14 | 2003-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 4 (gpr4) |
US20060252679A1 (en) | 2002-08-22 | 2006-11-09 | Mayumi Saki | Preventive and/or trerapeutic drgs for itch |
WO2004017994A1 (ja) | 2002-08-22 | 2004-03-04 | Kyowa Hakko Kogyo Co., Ltd. | 喘息の予防および/または治療剤 |
WO2005082904A1 (ja) * | 2004-02-26 | 2005-09-09 | Kyowa Hakko Kogyo Co., Ltd. | 好中球性炎症疾患の予防及び/または治療剤 |
JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Lck阻害剤としての縮合複素環 |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US20100152205A1 (en) | 2006-11-23 | 2010-06-17 | Novartis Ag | Cxcr2 inhibitors |
EP2094847A2 (en) | 2006-12-15 | 2009-09-02 | Novartis Ag | Inhibition of gpr4 |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
EA201000201A1 (ru) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций |
US20090291942A1 (en) | 2008-05-26 | 2009-11-26 | Ivan Cornella Taracido | Imidazo pyridine derivatives |
WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
US8207139B2 (en) | 2009-09-15 | 2012-06-26 | Li Yang | Function of GPR4 in vascular inflammatory response to acidosis and related methods |
-
2012
- 2012-03-26 US US13/429,726 patent/US8748435B2/en active Active
- 2012-03-28 UY UY0001033976A patent/UY33976A/es not_active Application Discontinuation
- 2012-03-29 AR ARP120101075A patent/AR085750A1/es not_active Application Discontinuation
- 2012-03-30 BR BR112013025001A patent/BR112013025001A2/pt not_active IP Right Cessation
- 2012-03-30 ES ES12715201.5T patent/ES2534444T3/es active Active
- 2012-03-30 AU AU2012235665A patent/AU2012235665A1/en not_active Abandoned
- 2012-03-30 PT PT127152015T patent/PT2694513E/pt unknown
- 2012-03-30 KR KR1020137028503A patent/KR20140023331A/ko not_active Application Discontinuation
- 2012-03-30 CA CA2831929A patent/CA2831929A1/en not_active Abandoned
- 2012-03-30 PL PL12715201T patent/PL2694513T3/pl unknown
- 2012-03-30 EA EA201391440A patent/EA201391440A1/ru unknown
- 2012-03-30 CN CN201280021124.7A patent/CN103502248B/zh not_active Expired - Fee Related
- 2012-03-30 JP JP2014501801A patent/JP5963843B2/ja not_active Expired - Fee Related
- 2012-03-30 MX MX2013011421A patent/MX2013011421A/es not_active Application Discontinuation
- 2012-03-30 TW TW101111548A patent/TW201245203A/zh unknown
- 2012-03-30 WO PCT/IB2012/051554 patent/WO2012131633A1/en active Application Filing
- 2012-03-30 EP EP12715201.5A patent/EP2694513B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2694513A1 (en) | 2014-02-12 |
EP2694513B1 (en) | 2015-01-07 |
WO2012131633A1 (en) | 2012-10-04 |
ES2534444T3 (es) | 2015-04-23 |
JP5963843B2 (ja) | 2016-08-03 |
EA201391440A1 (ru) | 2014-03-31 |
BR112013025001A2 (pt) | 2017-01-17 |
PL2694513T3 (pl) | 2015-06-30 |
KR20140023331A (ko) | 2014-02-26 |
US8748435B2 (en) | 2014-06-10 |
MX2013011421A (es) | 2013-12-09 |
TW201245203A (en) | 2012-11-16 |
AR085750A1 (es) | 2013-10-23 |
CA2831929A1 (en) | 2012-10-04 |
CN103502248B (zh) | 2015-03-11 |
JP2014514293A (ja) | 2014-06-19 |
AU2012235665A1 (en) | 2013-10-10 |
CN103502248A (zh) | 2014-01-08 |
PT2694513E (pt) | 2015-04-09 |
US20120252778A1 (en) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33943A (es) | Derivados espirocíclicos de isoxazolina como agentes antiparasitarios. | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34374A (es) | Benzilindazoles sustituidos | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY34156A (es) | Compuestos inhibidores de metaloenzimas | |
UY34515A (es) | Triazolopiridinas sustituidas | |
UY33925A (es) | Inhibidores tricíclicos de quinasas | |
UY34034A (es) | Triazolopiridinas | |
UY34039A (es) | Compuestos fungicidas | |
UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
UY34352A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
UY33978A (es) | Piridinonas bicíclicas nuevas. | |
UY34765A (es) | Compuestos novedosos. | |
UY34763A (es) | Inhibidores de la agregación plaquetaria | |
UY34006A (es) | Imidazopiridazinas | |
UY34318A (es) | ?derivados de isotiazolina útiles como compuestos insecticidas? | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
UY34004A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA | |
UY34550A (es) | Bencilpirazoles sustituidos | |
UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
UY34648A (es) | Amidas como inhibidores de pim | |
UY34302A (es) | COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA | |
UY34817A (es) | Tienopirimidinas | |
UY34523A (es) | Derivados de betulina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201019 |